PAK-LAM YU

# FECHNOLOGIES

INDUSTRIAL APPLICATIONS

ELSEVIER APPLIED SCIENCE

## FERMENTATION TECHNOLOGIES: INDUSTRIAL APPLICATIONS

Edited by

#### PAK-LAM YU

Department of Biotechnology, Massey University, Palmerston North, New Zealand





ELSEVIER APPLIED SCIENCE LONDON and NEW YORK

#### ELSEVIER SCIENCE PUBLISHERS LTD Crown House, Linton Road, Barking, Essex IG11 8JU, England

Sole Distributor in the USA and Canada ELSEVIER SCIENCE PUBLISHING CO., INC. 655 Avenue of the Americas, New York, NY 10010, USA

#### WITH 70 TABLES AND 144 ILLUSTRATIONS

© 1990 ELSEVIER SCIENCE PUBLISHERS LTD (except pp. 142–145)

© 1990 COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION—pp. 46–50, 67–72, 355–361

#### **British Library Cataloguing in Publication Data**

Fermentation technologies: industrial applications.

- 1. Industrial fermentation
- I. Yu, Pak-Lam 660.28449

ISBN 1-85166-516-1

Library of Congress CIP data applied for

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.

#### Special regulations for readers in the USA

This publication has been registered with the Copyright Clearance Center Inc. (CCC), Salem, Massachusetts. Information can be obtained from the CCC about conditions under which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside the USA, should be referred to the publisher.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Printed in Northern Ireland by The Universities Press (Belfast) Ltd.

#### **PREFACE**

The past decades have witnessed remarkable progess in those technologies that service the fermentation industries. One has only to consider the recent and dramatic increase in new journals addressing biotechnological subjects to realize the extent of developments in these areas and the continued growth in stature and maturity of the fermentation industry. But is there a gap developing between fundamental scientific knowledge and its industrial applications? Has the past decade focused sufficiently on the translation of laboratory observation into industrial practice, and with what success? What lessons of the past can be carried into the next ten years of biotechnology? What are the new developments of likely industrial importance?

The International Biotechnology Conference on Fermentation Technologies: Industrial Applications provided a forum for the discussion and exchange of views on these questions within a framework of topics which covered research, fermentation, manufacturing and processing. For the efficient application of fermentation technologies in the production of traditional and recombinant products, these different stages of development need to be treated as one continuous process, that is, researchers need to look at the technologies from more than one angle. This conference brought together researchers and other professionals to exchange their knowledge and experience in the whole field of biotechnology.

The proceedings of the conference are presented in this volume in five sections: Microbial Genetics and Recombinant Products, Microbial Physiology and Biotransformations, Yeast and Animal Cell Cultures, Bioreactor Design and Biosafety, and Downstream Processing. Each section includes plenary lectures, oral and poster papers. It is hoped that this volume will help to stimulate interest in further research and development into the application of fermentation technologies for the production of commercial products.

PAK-LAM YU

#### **CONTENTS**

Preface	V
Section I: Microbial Genetics and Recombinant Products	
Biotechnology and medicine: back to the future? (Plenary Lecture) J. Davies (Institut Pasteur, France)	3
Cloning genes from thermophiles: a review of current research R. H. McHale, D. Saul, M. Ashby, E. Lüthi, J. Whitefield and P. L. Bergquist ( <i>University of Auckland</i> , New Zealand)	9
Gene cloning and vector constructions in fermentative lactococci P. L. Yu, F. Xu (Massey University) AND L. E. PEARCE (New Zealand Dairy Research Institute, New Zealand)	15
The genetic manipulation of Clostridium acetobutylicum for potential improvements of the acetone butanol fermentation	22
Modern methods of enzyme production with emphasis on recombinant techniques	28
Secretory over-production of microbial enzymes using new host-vector systems	40
A temperature-inducible vector for the synthesis of recombinant proteins at temperatures below the threshold induction-temperature	46

Characterization of the cellulases and cellulase genes of Ruminococcus flavefaciens involved in cellulolytic fermentation	51
Prophage carrying Leuconostoc oenos and its implications on the malolactic fermentation of wine	55
Plasmid for the degradation of 2,4-dichlorophenoxyacetic acid (2,4-D) H. X. CHIURA, S. M. RAO BHAMIDIMARRI AND P. L. YU (Massey University, New Zealand)	59
Molecular breeding of meso-α,ε-diaminopimelate decarboxylase-overproducing strain	63
Enhancement of the levels of recombinant proteins synthesised in E. coli fermentations	67
The use of cycling to stabilise recombinant plasmids	73
Bacterial fermentation for the production of native and recombinant bacterial protein toxins	79
Section II: Microbial Physiology and Biotransformations	
Dotting and blotting, bubbling and boiling (Plenary Lecture)	87
Enhancement of <i>in vitro</i> stability and recovery of a proteinase produced by an extreme thermophile	97
An effective production method of glucoamylase in a novel solid-state culture system	103

Tallow—a potential carbon substrate for microbial enzyme production J. Holdsworth (DSIR Industrial Processing Division, New Zealand)	110
L-Amino acids production in continuous culture	116
Zymomonas ethanol process—laboratory to commercial evaluation H. W. Doelle (University of Queensland, Australia)	122
Temperature and ethanol effects on growth of Leuconostoc oenos R. V. ASMUNDSON AND W. J. KELLY (DSIR Biotechnology Division, New Zealand)	128
Increase of bacterial population by polyvinylpyridine added to a model system of continuous aerobic treatment	132
A microbial contribution to the problem of flue gas desulfurization K. L. Sublette, B. N. Dasu and K. H. Lee ( <i>University of Tulsa</i> , <i>USA</i> )	136
Transformation of high-carbohydrate food wastes into degradable plastics . P. V. Bonsignore, S. P. Tsai, T. S. Tsai and R. D. Coleman (Argonne National Laboratory, USA)	142
Exocellular inulinase of Bacillus subtilis 430A	146
Isolation of <i>Streptomyces</i> sp. producing glucose-tolerant $\beta$ -glucosidases and properties of the enzymes	150
Kaanga wai: a New Zealand Maori corn fermentation	155
The improvement of a traditional Thai fermented sausage by use of mixed starter cultures	159
Metabolic control of nisin biosynthesis in Lactococcus lactis subsp. lactis L. de Vuyst, G. de Poorter and E. Vandamme (State University of Ghent, Belgium)	166

fermentation	173
Possible physiological significance of transgalactosylation reactions of microbial β-galactosidases	178
Towards optimizing whey propionate production	184
Pectin liberation from sugar beet pulp by <i>Geotrichum</i> sp. protopectinase J. Hallaert, I. van Heetvelde, R. Seynaeve and E. Vandamme ( <i>State University of Ghent</i> , <i>Belgium</i> )	190
Fungal conversion of gallotannins into gallic acid	198
Microbial transformation of testosterone from cholesterol	204
CP-54,951, a chlorine-containing sulfamoyl adenine nucleoside antibiotic produced by the <i>Streptomyces rimosus</i> forma <i>paromomycinus</i> NRRL 2455 W. P. Cullen and M. T. Jefferson ( <i>Pfizer Inc.</i> , <i>USA</i> )	210
Determination of biofilm setting in hemodialysis devices: a model for determination of disinfection efficiency	214
Section III: Yeast and Animal Cell Cultures	
The genetic improvement of brewing and other ethanol producing yeasts (Plenary Lecture)	22]
The importance of magnesium ions in yeast biotechnology G. M. Walker, A. I. Maynard (Dundee Institute of Technology, UK) and C. G. W. Johns (National Institute for Higher Education, Ireland)	233

Mechanisms of ethanol inhibition in yeasts	241
Transfer of genes controlling utilization of starch (Sta 2) and fermentation of melibiose by protoplast fusion and probable single-chromosome transfer J. F. T. Spencer, D. M. Spencer, L. de Figueroa, J. M. Nougues and H. Heluane (PROIMI, Argentina)	247
Performance of hybrids between Kluyveromyces lactis and Saccharomyces cerevisiae obtained by protoplast fusion	253
Breeding of wine yeasts through protoplast fusion between champagne and wine yeasts	258
Consideration of the fermentation of concentrated whey solutions for ethanol production	264
Yeast single cell protein production from casein whey permeate J. N. CLARK (New Zealand Dairy Research Institute, New Zealand)	271
Extraction of yeast in fermentation vessels on an industrial scale: effect on the efficiency of fermentation	277
Continuous separation of cellobiose from a mixture of glucose and cellobiose using Candida tropicalis CBS 1920	281
Citrate production by yeast	285
Semi-solid fermentation of apple pomace using yeasts	292

applications in biotechnology	296
Glucose utilisation by Spodoptera frugiperda cells	302
In vitro production of monoclonal antibodies using perfusion systems L. J. Ward, M. J. Boland, W. T. Jones and D. E. Otter (DSIR Biotechnology Division, New Zealand)	308
Theory and practice in animal cell biotechnology ( <i>Plenary Lecture</i> ) R. E. Spier ( <i>University of Surrey</i> , <i>UK</i> )	314
Section IV: Bioreactor Design and Biosafety	
Bioreactor development: from enzymes to animal cells ( <i>Plenary Lecture</i> ) H. W. Blanch ( <i>University of California at Berkeley</i> , <i>USA</i> )	329
Bioreactors suitable to work with immobilized cells in waste water treatment	337
Novel bioreactors for the ABE fermentation using cells of Clostridium acetobutylicum immobilized by adsorption onto bonechar	343
The effect of substrate interaction on the design of bioreactors treating toxic or inhibitory compounds	349
A two-stage biofilm-floc anaerobic reactor for wastewater treatment K. D. Kirby (CSIRO Division of Biotechnology, Australia)	355
Production of 2,3-butanediol from glucose by <i>Klebsiella oxytoca</i> : factors influencing its production and application of high cell density continuous bioreactors	362
Expansion of a two-phase fluidized bed biofilm reactor	366

G. V. BHASKAR AND S. M. RAO BHAMIDIMARRI (Massey University, New Zealand)	3/0
Approximate solutions of a fluidised bed fermenter model A. A. PARSHOTAM, S. M. RAO BHAMIDIMARRI AND G. C. WAKE (Massey University, New Zealand)	374
Biosafety aspects of biotechnological processes: testing and evaluating equipment and components	378
Designing a pilot-scale fermentation facility for use with genetically modified microorganisms	383
Technical problems in large-scale containment of rDNA organisms D. E. Janssen, P. J. Lovejoy, M. T. Simpson and L. D. Kennedy (DSIR Biotechnology Division, New Zealand)	388
Application of a hazard and operability (HAZOP) study to a biological containment facility	394
Section V: Downstream Processing	
Bioprocessing aids in the purification of proteins	403
High yield, economic recovery of low value proteins	407
Product removal during ethanol and acetone-butanol-ethanol fermentation A. Friedel and R. Gapes ( <i>Technische Universität Wien</i> , <i>Austria</i> )	413
Filter validation	417

High resolution tangential filtration: mammalian cell harvesting A. Morgan (Millipore Australia Pty Ltd, Australia)	423
Industrial-scale crossflow membrane technology in downstream processing of bacterial antigens	427
Molecular thermodynamics of aqueous two-phase systems for bioseparations	433
Protein purification by two-step extraction followed by hydrophobic interaction chromatography	439

#### **SECTION I**

#### MICROBIAL GENETICS AND RECOMBINANT PRODUCTS



### BIOTECHNOLOGY AND MEDICINE: BACK TO THE FUTURE? JULIAN DAVIES

#### Institut Pasteur, Paris, France

At the beginning of the 90's, commercial sales of medical products developed from the applications of recombinant DNA technology total close to 2 billion US dollars worldwide. The major products are:

Product

110000	inppi i da di di
Interferons	anti-cancer
Insulin	diabetes
Growth hormone	congenital dwarfism
Plasminogen activator	cardiovascular disease
Erythropoietin	kidney deficiency
Hepatitis B	vaccine
Antibodies	diagnostic products
Nucleotide sequences	diagnostic products

Application

Although this market is impressive (it developed from nothing over the past 15 years!), it is still only a fraction of the total market in products of the biotechnology industries (food, drink, agriculture, antibiotics, enzymes etc.). However, applications of genetic engineering to the latter are being studied

intensively and we can anticipate increasing use of recombinant DNA products and genetically engineered micro-organisms over the next decade.

There are two aspects of this "modern" biotechnology which are worthy of further discussion. In spite of the fact that genetic engineering has permitted enormous advances in our understanding of human biology (immune system, endocrine system, neural system, etc.) by producing the means to isolate dozens of important physiologically active proteins such as cytokines and their receptors (many of the lymphokines available are pure and in quantity at the moment and were not even known ten years ago!); we still lack understanding of many of the fundamental processes required for the cloning, expression and production of a heterologous gene.

The focus of the first genetic engineering companies was to obtain a product as soon as possible. The products were all derived from single genes and the goals were obvious to all. Thus, there was a race, essentially, which started in the late 1970's and was won when one of the companies introduced a revenue-gaining therapeutic onto the market (either directly or through a licensee). The products involved were those mentioned above and the companies comprised Amgen, Biogen, Cetus, Genentech, Genex and others.

During this period, in the race to develop a product, there were many scientific and technical problems. The problems related to difficulties in

cloning, gene expression, protein isolation and purification. These problems were usually solved by trial and error and it is to be regretted that, in the majority of instances, no attempt was made to go back to find the fundamental basis of the problem.

To give two examples: translation blocks have been encountered on many occasions during attempts at heterologous gene expression. Despite the availability of strong promoters and faithful application of the "rules" for messenger RNA attachment to ribosomes and translation initiation, gene expression was often very poor. The reason(s) for these difficulties have still not been revealed and more profound and detailed studies would clearly provide more reliable "rules" for future applications. The same is true, to a large extent, for secretion: we simply do not know enough about the molecular interactions involved in these processes. attempts to hook-up heterologous genes to signal peptide sequences, to obtain secretion of the desired product, ended in failure. The second example concerns protein folding: it is well known that expression of a gene in a foreign organism leads to the formation of insoluble inclusion bodies. During the "biotech race" such inclusion bodies were solubilised in a variety of different ways and then processed subsequently under oxidising conditions to reform the active nature form of the protein. There was very